R&D channel feed

Vir’s GSK-al­lied flu pre­ven­tion an­ti­body fails PhII, sink­ing shares and late-stage hope

Last year

Amarin lays off US sales­force, names new CEO in shake­up

Last year

Af­ter year­long de­lay, FDA com­pletes in­spec­tion for No­var­tis, BeiGene's an­ti-PD-1 drug from Chi­na

Last year
FDA+

No­var­tis cuts PhII obe­si­ty can­di­date as it fi­nal­izes San­doz spin­off

Last year
Pharma

Neumo­ra goes big with three PhI­II de­pres­sion stud­ies, new CEO from Ab­b­Vie’s C-suite

Last year
People

No­vo Nordisk inks re­search deal with RNA start­up with new de­liv­ery ap­proach

Last year
Deals

J&J's Ry­bre­vant-chemo com­bo shows pos­i­tive PFS da­ta in con­fir­ma­to­ry study

Last year
Pharma

No­var­tis to buy siR­NA de­vel­op­er DTx Phar­ma for up to $1B

Last year
Deals

Apel­lis shares tum­ble on re­ports of eye in­flam­ma­tion in pa­tients tak­ing Syfovre

Last year
Pharma

Up­dat­ed: Eli Lil­ly ex­pects FDA de­ci­sion on Alzheimer’s drug by end of year as it un­veils full PhI­II da­ta

Last year
Pharma

Ar­genx looks for quick la­bel ex­pan­sion for sub­cu­ta­neous Vyv­gart with PhII da­ta — shares soar

Last year
Pharma

Bridge­Bio's AT­TR-CM tri­al odyssey ends with a win, show­ing pos­i­tive mor­tal­i­ty and hos­pi­tal­iza­tion da­ta

Last year

Sin­gle in­jec­tion of Al­ny­lam's RNAi ther­a­py re­duces Alzheimer's-linked pro­teins by 65% for six months

Last year

Bridge­Bio's make-or-break read­out is slat­ed for Mon­day, as CEO posts a cryp­tic mes­sage about Odysseus

Last year

Cari­bou’s off-the-shelf CAR-T ther­a­py shows hints of dura­bil­i­ty in ear­ly cut of da­ta 

Last year
Cell/Gene Tx

Roivant dis­cussing sale of its Pfiz­er-part­nered UC drug to Roche for $7B, ac­cord­ing to re­port

Last year
Deals

The­seus goes back to pre­clin­i­cal mode af­ter ax­ing lead tar­get­ed ther­a­py over tol­er­a­bil­i­ty con­cerns, shares plum­met

Last year

Pfiz­er clin­i­cal tri­al reg­istry aims to re­cruit one mil­lion peo­ple for re­search

Last year
Pharma
Marketing

First Wave’s mid-stage tri­al for yeast-de­rived cys­tic fi­bro­sis drug ‘like­ly’ failed, com­pa­ny says

Last year

From hours to min­utes? Genen­tech says Ocre­vus sub­cu­ta­neous for­mu­la­tion works just as well as IV

Last year

With biggest weight loss da­ta in hand, Eli Lil­ly races to start trio of PhI­II tri­als for its ‘triple-G’ can­di­date next month

Last year
Pharma

How many pa­tients could ben­e­fit from cus­tom ge­net­ic ther­a­pies? Tim­o­thy Yu nar­rows in on an an­swer

Last year
Cell/Gene Tx

In­cyte says JAK cream clears PhI­II eczema tri­al in chil­dren, but an­a­lysts are still watch­ing safe­ty

Last year
Pharma

ADC Ther­a­peu­tics paus­es Zyn­lon­ta tri­al en­roll­ment af­ter sev­en pa­tient deaths, five se­ri­ous safe­ty events

Last year
First page Previous page 78798081828384 Next page Last page
A service from the Financial Times